Actinium Pharmaceuticals, Inc. (ATNM)
USD 1.29
(-7.19%)
USD 1.29
(-7.19%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 52 Million USD | 45.76% |
| 2022 | 35.13 Million USD | 34.57% |
| 2021 | 26.1 Million USD | 16.59% |
| 2020 | 22.39 Million USD | 1.46% |
| 2019 | 22.07 Million USD | -7.37% |
| 2018 | 23.82 Million USD | -11.46% |
| 2017 | 26.91 Million USD | 0.24% |
| 2016 | 26.84 Million USD | 8.13% |
| 2015 | 24.82 Million USD | 10.45% |
| 2014 | 22.48 Million USD | 241.25% |
| 2013 | 6.58 Million USD | -17.11% |
| 2012 | 7.94 Million USD | 82555.21% |
| 2011 | 9615.00 USD | -62.15% |
| 2010 | 25.4 Thousand USD | 74.79% |
| 2009 | 14.53 Thousand USD | -44.98% |
| 2008 | 26.41 Thousand USD | 120.29% |
| 2007 | 11.99 Thousand USD | -31.6% |
| 2006 | 17.53 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 12.22 Million USD | 32.37% |
| 2024 Q1 | 9.38 Million USD | -8.25% |
| 2023 FY | 51.21 Million USD | 45.76% |
| 2023 Q3 | 14.35 Million USD | -8.25% |
| 2023 Q2 | 15.64 Million USD | 35.03% |
| 2023 Q1 | 11.58 Million USD | 2.59% |
| 2023 Q4 | 10.22 Million USD | -28.75% |
| 2022 Q3 | 9.84 Million USD | 24.69% |
| 2022 FY | 35.13 Million USD | 34.57% |
| 2022 Q1 | 6.1 Million USD | -24.37% |
| 2022 Q2 | 7.89 Million USD | 29.34% |
| 2022 Q4 | 11.29 Million USD | 14.7% |
| 2021 Q2 | 5.34 Million USD | -10.89% |
| 2021 Q4 | 8.07 Million USD | 20.43% |
| 2021 FY | 26.1 Million USD | 16.59% |
| 2021 Q1 | 5.99 Million USD | -6.85% |
| 2021 Q3 | 6.7 Million USD | 25.48% |
| 2020 Q3 | 5.61 Million USD | 20.4% |
| 2020 FY | 22.39 Million USD | 1.46% |
| 2020 Q2 | 4.66 Million USD | -17.97% |
| 2020 Q1 | 5.68 Million USD | 22.65% |
| 2020 Q4 | 6.43 Million USD | 14.64% |
| 2019 Q1 | 5.69 Million USD | -10.44% |
| 2019 FY | 22.07 Million USD | -7.37% |
| 2019 Q2 | 5.08 Million USD | -10.76% |
| 2019 Q3 | 6.65 Million USD | 30.79% |
| 2019 Q4 | 4.63 Million USD | -30.35% |
| 2018 Q3 | 6.19 Million USD | 26.14% |
| 2018 FY | 23.82 Million USD | -11.46% |
| 2018 Q1 | 6.35 Million USD | 22.03% |
| 2018 Q2 | 4.91 Million USD | -22.68% |
| 2018 Q4 | 6.36 Million USD | 2.68% |
| 2017 FY | 26.91 Million USD | 0.24% |
| 2017 Q4 | 5.2 Million USD | -22.23% |
| 2017 Q3 | 6.69 Million USD | -7.06% |
| 2017 Q2 | 7.2 Million USD | -7.72% |
| 2017 Q1 | 7.8 Million USD | 14.34% |
| 2016 Q4 | 6.82 Million USD | -3.86% |
| 2016 Q2 | 6.91 Million USD | 15.26% |
| 2016 Q3 | 7.1 Million USD | 2.64% |
| 2016 Q1 | 6 Million USD | 21.99% |
| 2016 FY | 26.84 Million USD | 8.13% |
| 2015 FY | 24.82 Million USD | 10.45% |
| 2015 Q4 | 4.91 Million USD | 6.04% |
| 2015 Q3 | 4.63 Million USD | -37.34% |
| 2015 Q2 | 7.4 Million USD | -5.86% |
| 2015 Q1 | 7.86 Million USD | 14.45% |
| 2014 Q4 | 6.87 Million USD | -2.45% |
| 2014 FY | 22.48 Million USD | 241.25% |
| 2014 Q1 | 4.13 Million USD | 178.81% |
| 2014 Q2 | 4.42 Million USD | 6.92% |
| 2014 Q3 | 7.04 Million USD | 59.22% |
| 2013 Q1 | 2.01 Million USD | -74.55% |
| 2013 Q2 | 1.47 Million USD | -26.91% |
| 2013 Q3 | 1.6 Million USD | 9.04% |
| 2013 Q4 | 1.48 Million USD | -7.75% |
| 2013 FY | 6.58 Million USD | -17.11% |
| 2012 FY | 7.94 Million USD | 82555.21% |
| 2012 Q1 | 7410.00 USD | 547.73% |
| 2012 Q3 | 2.39 Million USD | 185.87% |
| 2012 Q4 | 7.93 Million USD | 230.56% |
| 2012 Q2 | 839.33 Thousand USD | 11227.11% |
| 2011 FY | 9615.00 USD | -62.15% |
| 2011 Q1 | 2680.00 USD | -60.41% |
| 2011 Q2 | 3361.00 USD | 25.41% |
| 2011 Q3 | 2430.00 USD | -27.7% |
| 2011 Q4 | 1144.00 USD | -52.92% |
| 2010 Q1 | 6513.00 USD | 3.15% |
| 2010 Q4 | 6769.00 USD | -14.77% |
| 2010 Q3 | 7942.00 USD | 89.95% |
| 2010 FY | 25.4 Thousand USD | 74.79% |
| 2010 Q2 | 4181.00 USD | -35.81% |
| 2009 Q3 | 2232.00 USD | 5.73% |
| 2009 Q1 | 3878.00 USD | -38.6% |
| 2009 FY | 14.53 Thousand USD | -44.98% |
| 2009 Q4 | 6314.00 USD | 182.89% |
| 2009 Q2 | 2111.00 USD | -45.56% |
| 2008 Q1 | 9705.00 USD | 115.67% |
| 2008 Q2 | 8304.00 USD | -14.44% |
| 2008 Q3 | 2094.00 USD | -74.78% |
| 2008 Q4 | 6316.00 USD | 201.62% |
| 2008 FY | 26.41 Thousand USD | 120.29% |
| 2007 Q3 | 4653.00 USD | 63.84% |
| 2007 Q2 | 2840.00 USD | 752.87% |
| 2007 FY | 11.99 Thousand USD | -31.6% |
| 2007 Q1 | -435.00 USD | -105.8% |
| 2007 Q4 | 4500.00 USD | -3.29% |
| 2006 Q3 | 10.03 Thousand USD | 0.0% |
| 2006 Q4 | 7504.00 USD | -25.18% |
| 2006 FY | 17.53 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 32.07 Million USD | -62.118% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -461.081% |
| Armata Pharmaceuticals, Inc. | 11.64 Million USD | -346.399% |
| Azitra, Inc. | 8.3 Million USD | -526.337% |
| Can-Fite BioPharma Ltd. | 8.93 Million USD | -481.797% |
| Chromocell Therapeutics Corporation | 6.86 Million USD | -657.78% |
| Calidi Biotherapeutics, Inc. | 28.99 Million USD | -79.363% |
| CEL-SCI Corporation | 31.47 Million USD | -65.208% |
| iBio, Inc. | 16.85 Million USD | -208.447% |
| Lineage Cell Therapeutics, Inc. | 33 Million USD | -57.545% |
| MAIA Biotechnology, Inc. | 20.18 Million USD | -157.655% |
| Matinas BioPharma Holdings, Inc. | 24.86 Million USD | -109.159% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -273.259% |
| NovaBay Pharmaceuticals, Inc. | 12.89 Million USD | -303.171% |
| NanoViricides, Inc. | 8.51 Million USD | -510.619% |
| Oragenics, Inc. | 5.45 Million USD | -853.805% |
| BiomX Inc. | 26.81 Million USD | -93.932% |
| BiomX Inc. | 26.81 Million USD | -93.932% |
| Protalix BioTherapeutics, Inc. | 32.05 Million USD | -62.239% |
| Palatin Technologies, Inc. | 34.67 Million USD | -49.987% |
| Scorpius Holdings, Inc. | 39.81 Million USD | -30.604% |
| Theriva Biologics, Inc. | 21.43 Million USD | -142.644% |